Detalles de la búsqueda
1.
A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation.
Transfus Med Hemother;
50(6): 475-490, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38089497
2.
Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study.
Transfus Med Hemother;
50(5): 403-416, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37899991
3.
Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.
Eur J Haematol;
107(5): 529-542, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34270825
4.
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
Hematol Oncol;
38(3): 244-256, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32067259
5.
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.
Eur J Haematol;
103(3): 255-267, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31231828
6.
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Br J Haematol;
179(4): 586-597, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28961309
7.
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Lancet Oncol;
16(16): 1691-9, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26549589
8.
Donor-cell leukemia with novel genetic features 2 years after sex-mismatched T cell-depleted haploidentical stem cell transplantation.
Ann Hematol;
99(4): 899-901, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32086586
9.
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Lancet;
381(9873): 1203-10, 2013 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23433739
10.
Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM.
Cancers (Basel);
13(6)2021 Mar 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-33809431
11.
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.
Leukemia;
35(9): 2517-2525, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33603142
12.
A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).
Lung Cancer;
57(2): 181-6, 2007 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-17442447
13.
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
J Clin Oncol;
23(15): 3383-9, 2005 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-15908650
14.
Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer.
Lung Cancer;
36(3): 303-7, 2002 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-12009242
15.
Maintenance therapy for multiple myeloma with particular emphasis on thalidomide.
Onkologie;
29(12): 582-90, 2006 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17202830
16.
Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot study.
Onkologie;
28(12): 647-50, 2005 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-16330888
Resultados
1 -
16
de 16
1
Próxima >
>>